Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Align Technology (NASDAQ: ALGN) and its peers.
The dental equipment and technology industry encompasses companies that manufacture orthodontic products, dental implants, imaging systems, and digital tools for dental professionals. These companies benefit from recurring revenue streams tied to consumables, ongoing maintenance, and growing demand for aesthetic and restorative dentistry. However, high R&D costs, significant capital investment requirements, and reliance on discretionary spending make them vulnerable to economic cycles. Over the next few years, tailwinds for the sector include innovation in digital workflows, such as 3D printing and AI-driven diagnostics, which enhance the efficiency and precision of dental care. However, headwinds include economic uncertainty, which could reduce patient spending on elective procedures, regulatory challenges, and potential pricing pressures from consolidated dental service organizations (DSOs).
The 4 dental equipment & technology stocks we track reported a strong Q2. As a group, revenues beat analysts’ consensus estimates by 1.4% while next quarter’s revenue guidance was 1.3% below.
Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 6.7% since the latest earnings results.
Weakest Q2: Align Technology (NASDAQ: ALGN)
Pioneering an alternative to traditional metal braces with nearly invisible plastic aligners, Align Technology (NASDAQ: ALGN) designs and manufactures Invisalign clear aligners, iTero intraoral scanners, and dental CAD/CAM software for orthodontic and restorative treatments.
Align Technology reported revenues of $1.06 billion, up 4.3% year on year. This print was in line with analysts’ expectations, but overall, it was a mixed quarter for the company with a beat of analysts’ EPS estimates but revenue guidance for next quarter slightly missing analysts’ expectations.
Align Technology delivered the weakest performance against analyst estimates in the group. The market seems disappointed with the results as the stock is down 12.2% since reporting and currently trades at $158.04.
Read our full report on Align Technology here, it’s free.
Best Q2: Envista (NYSE: NVST)
Uniting more than 30 trusted brands including Nobel Biocare, Ormco, and DEXIS under one corporate umbrella, Envista Holdings (NYSE: NVST) is a global dental products company that provides equipment, consumables, and specialized technologies for dental professionals.
Envista reported revenues of $730.5 million, up 7.1% year on year, outperforming analysts’ expectations by 2%. The business had an exceptional quarter with a solid beat of analysts’ full-year EPS guidance estimates and a beat of analysts’ EPS estimates.
Envista pulled off the fastest revenue growth among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 4.8% since reporting. It currently trades at $27.27.
Is now the time to buy Envista? Access our full analysis of the earnings results here, it’s free.
Dentsply Sirona (NASDAQ: XRAY)
With roots dating back to 1877 when it introduced the first dental electric drill, Dentsply Sirona (NASDAQ: XRAY) manufactures and sells professional dental equipment, technologies, and consumable products used by dentists and specialists worldwide.
Dentsply Sirona reported revenues of $898 million, down 4.1% year on year, exceeding analysts’ expectations by 0.6%. It may have had the worst quarter among its peers, but its results were still good as it also locked in a beat of analysts’ EPS estimates and an impressive beat of analysts’ full-year EPS guidance estimates.
Dentsply Sirona delivered the slowest revenue growth of the whole group. As expected, the stock is down 14.2% since the results and currently trades at $11.30.
Read our full analysis of Dentsply Sirona’s results here.
Henry Schein (NASDAQ: HSIC)
With a vast inventory of over 300,000 products stocked in distribution centers spanning more than 5.3 million square feet worldwide, Henry Schein (NASDAQ: HSIC) is a global distributor of healthcare products and services primarily to dental practices, medical offices, and other healthcare facilities.
Henry Schein reported revenues of $3.46 billion, up 6.7% year on year. This print surpassed analysts’ expectations by 2.6%. Overall, it was a strong quarter as it also put up a solid beat of analysts’ organic revenue estimates and a beat of analysts’ EPS estimates.
Henry Schein pulled off the biggest analyst estimate beat in the group. The stock is up 4.3% since reporting and currently trades at $90.27.
Read our full, actionable report on Henry Schein here, it’s free.
Market Update
Over the past year, investors have been forced to repeatedly answer the same question: what is the market’s biggest risk? The answer has changed several times, and each shift has reshaped market leadership.
Late in 2025 and early 2026, artificial intelligence became the market’s primary uncertainty. Investors questioned whether AI would erode software pricing power and weaken competitive moats as AI made it easier to replicate once-differentiated products.
By the spring, technology took a back seat to geopolitics. The U.S. conflict with Iran briefly became the market’s dominant narrative, raising concerns about oil prices, inflation, and global growth. But as energy markets remained orderly and fears of a prolonged supply disruption faded, investors quickly turned their focus back to fundamentals.
Want to invest in winners with rock-solid fundamentals? Check out our Top 6 Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
